New IMPACT Publications

Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJUI (Sept, 2010, 14, doi: 10.1111/j.1464-410X.2010.09648.x.

 Mitra AV, Jameson C, Barbachano Y, et al. Elevated expression of Ki-67 identifies aggressive prostate cancer but does not distinguish BRCA1 and BRCA2 mutation carriers. Oncol Rep. 2010;23(2):299-305.

Whitaker H, Kote-Jarai Z, Ross-Adams H, Warren A, Burge A, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman G, Evans DG, Blanco I, Mercer S, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Lilja H, Easton D, The IMPACT Study Steering Committee, The IMPACT Study Collaborators, Cooper C, Eeles R, Neal, D. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS (Accepted for publication Sept 2010)

Anita V Mitra, et al. (2007). A review of targeted screening for prostate cancer: introducing the IMPACT Study. British Journal of Urology International 2007.

Home